Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant epirubicin + docetaxel with or without capecitabine in early HER2-negative or HER2-positive breast cancer
2004-002030-19Phase 3Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Jan 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, epirubicin, docetaxel, trastuzumab and filgrastim in breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Pathological complete remission rate. Started Jan 2005; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-002030-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002030-19.